Inari Medical price target lowered to $52 from $61 at Truist

Truist analyst Richard Newitter lowered the firm’s price target on Inari Medical (NARI) to $52 from $61 and keeps a Hold rating on the shares. While the firm’s intra-quarter conversations with surgeons and companies suggests the market is likely growing fairly steadily at or even slightly above normal rates, Inari will likely continue to lose some additional share to Penumbra (PEN) in an expanding thrombectomy category, the analyst tells investors in a research note.